The peripheral benzodiazepine receptor (PBR) is a mitochondrial protein that is highly expressed in phagocytic inflammatory cells: macrophages in the periphery and activated microglia in the central nervous system (1) . Imaging of PBRs can localize inflammation in brain associated with increased densities of these phagocytic cells. For example, several PET studies using the PBR radioligand 11 C-PK 11195 have localized inflammation associated with acute neurologic and neurodegenerative disorders (2) . In addition to their high expression in phagocytic cells, PBRs are located on the mitochondrial outer membrane in several organs, including kidney, lung, and heart wall (3) . PBRs in these peripheral organs will temporarily bind PBR ligands and reduce the amount that is delivered to brain.
A new class of high-affinity PBR ligands has been synthesized with an aryloxyanalide backbone (4) (5-8), instead of the isoquinoline structure of PK 11195. Our laboratory synthesized one such aryloxyanalide, 11 C-PBR28 ([methyl- 11 C]N-acetyl-N-(2-methoxybenzyl)-2-phenoxy-5-pyridinamine), which gave promising imaging results in monkeys and rats. After injection of 11 C-PBR28 in monkeys, uptake of radioactivity in brain could be quantified relative to plasma concentrations and had a high percentage of specific receptor binding (.85% of total brain radioactivity) (9) . Furthermore, PET with 11 C-PBR28 in rats could localize and quantify inflammation surrounding a stroke induced with occlusion of a cerebral artery (10) .
The primary goals of the current study were to estimate the human radiation-absorbed dose from 11 C-PBR28 and to determine whether results from monkeys accurately predict those obtained directly from humans. In addition, we scanned one unusual human subject who appeared to lack binding of 11 C-PBR28 to PBR in brain. Decreased uptake in brain was not caused by rapid metabolism, as the plasma clearance of 11 C-PBR28 in arterial samples was similar to that of other healthy subjects. We later performed wholebody imaging on this subject and found minimal uptake in peripheral organs with high densities of PBRs-namely, lung, kidney, spleen, and heart wall. In summary, this subject behaved as if he lacked the PBR binding protein or as if his PBRs had minimal affinity for 11 C-PBR28. We do not know the reason(s) for the unusual finding in this healthy individual. Nevertheless, this subject provided the opportunity to assess the effect of receptor availability on radiation exposure.
MATERIALS AND METHODS

Radiopharmaceutical Preparation
11 C-PBR28 was prepared by the 11 C-methylation of its desmethyl analog with 11 C-iodomethane, itself prepared from cyclotronproduced 11 C-carbon dioxide, and purified with reverse-phase high-performance liquid chromatography (HPLC). Preparations were conducted according to our exploratory Investigational New Drug Application 73,935, submitted to the U.S. Food and Drug Administration and a copy of which is available at: http://kidb. bioc.cwru.edu/snidd/. The radioligand was obtained in high radiochemical purity (.99%), and the specific activity at the time of injection 5 183 6 76.2 GBq/mmol (n 5 9 batches), as assessed by analytic reverse-phase HPLC with these and subsequent numeric data expressed as mean 6 SD.
Human Subjects
Our use of 11 C-PBR28 in human subjects was approved the Radiation Safety Committee of the National Institutes of Health and the Institutional Review Board of the National Institute of Mental Health. Seven healthy volunteers participated: 4 males and 3 females, 31 6 9 y of age, 77 6 15 kg body weight. All subjects were free of current medical and psychiatric illness on the basis of history, physical examination, electrocardiogram (ECG), urinalysis including drug screening, and blood tests (complete blood count, serum chemistries, thyroid function test, and antibody screening for syphilis, HIV, and hepatitis B). Approximately 24 h after the PET scan, subjects returned to repeat the urinalysis and blood tests.
Subject 7 showed no binding to 11 C-PBR28. He was a 26-y-old Latin American male in excellent health, with no significant prior medical history and taking no medications at the time of the whole-body scan.
Animal Subjects
Two male rhesus monkeys (4.5 and 5.0 kg) were scanned. To allow intubation, animals were anesthetized with propofol (1.2-4 mg/kg intravenously), ketamine (10-15 mg/kg intramuscularly), and glycopyrrolate (0.15-0.2 mg/kg intravenously). After transportation to the PET suite, the animals were anesthetized with isoflurane (1.5%-2%) for the duration of the scanning experiment. To minimize the effects of ketamine, scans started at least 90 min after its administration. Body temperature was controlled by an air-circulating heating device (Bair Hugger, model 505; Arizant Healthcare). The ECG, pulse, and respiration rate were monitored throughout the experiment.
Human PET and Image Analysis
Subjects underwent transmission and dynamic emission scans on an Advance tomograph (GE Healthcare). Transmission scans using 68 Ge rods were obtained on 7 segments of 15 cm each, the axial view of the scanner, from the top of the head to the midthigh. Each transmission scan lasted 3 min. To minimize extraneous motion, all subjects wore a mask that affixed their head in a single position and had their arms and abdomen wrapped with body-restraining sheets. Blood pressure, pulse, and respiration rates were obtained before the administration of 11 C-PBR28 and at 4 points during the emission scans.
After intravenous bolus administration of 11 C-PBR28 (651 6 111 MBq), dynamic emission scans of 14 frames were acquired by serial imaging of the body in the 7 contiguous segments. The durations of the initial frames were 15 s at each segment, followed by frames of increasing duration, with six 3-s intervals to move the bed to the next section and 13 s to return back to the first bed position. The total scanning time was ;120 min (4 · 15 s, 3 · 30 s, 3 · 60 s, 3 · 2 min, and 1 · 4 min for each of the 7 body segments).
The 245 (35 slices · 7 beds) original tomographic PET images of human subjects were reinterpolated into isotropic voxels and compressed into whole-body images in 2 different ways, 2-dimensional (2D) planar and bisected: (a) 2D planar. All voxels were compressed into a single image in the coronal orientation; as shown in ½Fig: 1 Image analysis was performed using PMOD 2.8 (pixelwise modeling computer software; PMOD Group). Regions of interest were drawn in source organs that could be identified on 6 of the subjects: brain, heart, lungs, spleen, liver, kidneys, gallbladder (visible in only 3 subjects), and urinary bladder. To avoid the contamination of high lung activity into the heart, we compressed 17-20 transverse slices from the tip of the apex to the base of the myocardium in head to feet direction. One unusual subject (subject 7) had visible organ activity in only the liver, gallbladder, and jnm044842-tp n 11/10/07 urinary bladder. Large regions of interest were placed to ensure that all accumulated radioactivity in each organ was included.
Animal PET and Image Analysis
Three whole-body baseline scans were acquired on the GE Advance tomograph in 4 segments of the body (head to thigh) in frames of increasing duration (75 s to 15 min) (4 · 15 s, 4 · 30 s, 8 · 1 min, 4 · 2 min, 2 · 4 min) for a total scan time of ;120 min. A urinary catheter was inserted and clamped so that the radioactivity overlaying the bladder represented the total urinary excretion during the scanning interval. Data acquisition during PET started immediately after the intravenous injection of 11 C-PBR28 (370 6 59.9 MBq) via the posterior tibal vein.
A preblocking scan was performed on 1 monkey after its baseline scan, in which nonradioactive PK 11195 (10.7 mg/kg intravenously) was injected 3 min before the radioligand. The pretreatment interval of 3 min was selected because the uptake and washout of PK 11195 is rapid in monkey brain (11) .
The tomographic PET images were compressed into a single 2D planar image as previously described. Regions of interest were drawn on visually identifiable source organs: brain, heart, lungs, spleen, kidneys, liver, and urinary bladder.
Residence Time Calculations for Humans and Monkeys
The organ activity values were corrected for recovery relative to a large region of interest over the entire body for each frame. The injected activity value for each source organ at every time point was multiplied by 100/X, where X is the measured recovery for the individual frame. In humans, the measured recovery averaged 93% for all frames. In monkeys, the measured recovery was only 33% for the first frame but was an average of 90% for the remaining frames. The low recovery of the first frame was presumably due to the injection site being below the field of view.
The ''remainder of body'' was calculated for each time point as the decayed value of the original injected activity minus that in the identified source organs.
Time-activity curves for the source organs were plotted as the percentage of injected activity versus time. For simplicity, we chose to use a trapezoidal integration to calculate the area under the curve up to the termination of acquisition for each source organ, including the urinary bladder. The area under the curve after the acquisition of the last image to infinity was calculated by assuming that the decline in radioactivity after this time point occurred by physical decay only, without any further biologic clearance. The area under the curve of the percentage injected activity from time zero to infinity is equivalent to the residence time for the human.
The residence times for all of the source organs were summed and subtracted from the fixed theoretic value of t 1/2 /ln 2 5 0.49 h to calculate the residence time of the remainder in the body for each subject. t 1/2 is the radioactive half-life of 11 C (0.33 h).
Note that residence time is calculated from the area under the plot of decayed activity versus time. In contrast, Figures 3, 4 , and 6 in this article plot decay-corrected activities to show uptake and washout of radioactive compounds.
For monkeys, residence times were calculated as described but converted into corresponding human values by multiplication with a factor to scale organ and body weights: 
Organ Absorbed Dose
Radiation-absorbed doses were calculated by entering the residence times of all source organs for each subject and monkey into the OLINDA 1.0/EXM computer program (14) using the model for a 70-kg adult male. We were unable to fit the accumulated urinary bladder activity to a biexponential curve and, thus, did not use the dynamic bladder model. Instead, residence times of the bladder were calculated in the same fashion as the other source organs.
RESULTS
Human Subjects with Expected Biodistribution
Intravenous injection of 11 C-PBR28 (carrier PBR28, 0.019 6 0.006 mg/kg, n 5 5) produced no clinically observable effects. Blood pressure, pulse, and respiratory rate during the 2 h after injection as well as blood and urine tests on the next day had clinically insignificant changes. After injection of 11 C-PBR28, brain, lungs, liver, heart, kidneys, spleen, and urinary bladder were visually identified as source organs with moderate-to-high activity in most subjects (Fig. 1) . The gallbladder was not visualized in 3 subjects, and the spleen, lungs, and kidneys were not visualized in 1 subject-namely, unusual subject 7 ( ½Fig: 2 Fig. 2) . Lungs had the highest uptake, with a peak value of 35% injected activity (n 5 6) during the first frame acquisition (0-2 min). Peak values of the percentage injected activity in liver, kidneys, brain, spleen, heart, and gallbladder were 15%, 14%, 5%, 4.5%, 3.7%, and 1%, respectively, all occurring within 10 min (Figs. 3A ½Fig: 3 and 3B; excluding heart). Subject 7 had significantly less uptake in organs with high densities of PBR-namely, lung, heart, brain, spleen, and kidneys (Figs. 3C and 3D ). For subject 7, the peak lung uptake (10%) was lower than the average lung uptake of subjects 1-6 (35%), and the washout from his brain was faster ½Fig: 4 than that in the other volunteers (Fig. 4) .
The residence times of organs listed in ( ½Table 1  Table 1) were calculated from 2D planar images in healthy subjects 1-6 and separately for the unusual subject 7. Cumulative activity in the urinary bladder could not be fitted with a mono-or biexponential curve. Thus, a dynamic bladder model was not applied. For subjects 1-6, the effective dose was 6.6 mSv/MBq, and the 3 organs with highest radiation-absorbed doses were kidneys (53 mSv/MBq), spleen (26 mSv/MBq), and lungs (22 mSv/MBq) ( ½Table 2 Table 2 ). The use of 2D planar images may have significantly increased the activity of some organs by including tissue anterior and posterior to the organ. Of the identified sources, kidneys and heart were probably the most contaminated by adjacent activity and their residence times were also calculated from images with less compression. Because of its location, the kidney was recalculated with the posterior of the 2 bisected images. The heart was also recalculated with the superior-inferior compression of the chest. See the Materials and Methods for details on the image analysis. Compared with 2D planar analysis, these 2 methods jnm044842-tp n 11/10/07 with less contamination decreased the residence times and radiation exposures of kidney and heart. For example, the radiation exposure of heart decreased from 11.2 to 7.8 mSv/MBq and that of kidney decreased from 52.6 to 29.9 mSv/MBq. Nevertheless, the effective dose remained 6.6 mSv/MBq. In a similar manner, the dose to the kidneys decreased 43%, from 52.6 to 29.9 mSv/MBq. Nevertheless, the effective dose was minimally affected, changing from 6.6 to 6.2 mSv/MBq.
Human Subject with Unexpected Biodistribution
Compared with subjects 1-6, subject 7 had decreased activity in organs with high PBR densities-that is, brain, lungs, heart, spleen, and kidneys (Figs. 3C and 3D ). In fact, spleen, lungs, and kidneys could not be identified visually in this subject (Fig. 2) . Furthermore, the activities in liver and gallbladder of subject 7 were much higher than the mean of subjects 1-6 (Figs. 3C and 3D ).
The dosimetry estimates in subject 7 reflected biodistribution and tended to decrease radiation burden to organs with high PBR densities and increased radiation burden to organs associated with excretion and metabolism. For example, among organs with high PBR densities, the doses were decreased in brain (31%), lungs (56%), heart (29%), spleen (91%), and kidneys (94%) relative to that of subjects 1-6. In contrast, doses were increased to liver (65%), gallbladder wall (218%), and urinary bladder wall (20%). Overall, the effective dose was 28% less compared with that of subjects 1-6 (supplemental Table 1; supplemental Tables 1 and 2 are available online only at http://jnm.snmjournals.org).
Monkey Biodistribution
Injection of 11 C-PBR28 caused no change in ECG, heart, or respiration rates. Gallbladder, lungs, spleen, heart, brain, kidneys, liver, and urinary bladder were visually identified as organs with moderate-to-high activity ( ½Fig: 5 Fig. 5 ). Uptake of Decay-corrected timeactivity curves for visually identifiable organs from the average of subjects 1-6 (A and B) and the unusual subject 7 (C and D). Kidneys (C) and spleen (D) could not be seen in subject 7. Graph becomes too cluttered if SD error bars are included. Distribution of data is exemplified by the % coefficient of variation (SD/mean) at 60 min for A and B, with lungs at 40%, liver at 28%, gallbladder at 29%, and brain at 35%. jnm044842-tp n 11/10/07 11 C-PBR28 was highest in the lungs, with a peak of 50% injected activity occurring during the first frame (0-1.15 min). Peak uptake in kidneys, heart, liver, brain, and urinary bladder were 19.5%, 7%, 10%, 4.2%, and 0.8% standardized uptake value, respectively (Fig. 6 ) ½Fig: 6 .
Human residence times were extrapolated from 3 imaging sessions in 2 monkeys ( ½Table 3  Table 3 ). Similar to the human bladder, cumulative urinary activity in the monkey could not be fitted with a biexponential curve; thus, the dynamic bladder model was not applied. The human effective dose estimated from monkey whole-body imaging was 10.3 mSv/MBq (supplemental Table 1 ). The 3 organs with the highest radiation burden (mSv/MBq) were lungs (70.5), kidneys (43.1), and brain (19.5).
Comparison of Monkey and Human Biodistribution Data
The overall distribution of activity was similar in the baseline monkey and typical healthy humans (subjects 1-6). For example, both had high uptake in lungs, kidney, and spleen ( Figs. 1 and 5A ). To estimate human dosimetry from the monkey biodistribution data, organ weight and body mass were used for allometric scaling (Materials and Methods). The human effective dose was overestimated by 60% using the monkey data, with exposures to individual organs both over-and underestimated. The overestimation of effective dose was primarily caused by higher exposures in 3 organs, all of which have high PBR densities. Compared with jnm044842-tp n 11/10/07
human biodistribution results, the monkey dose was elevated in brain (4-fold), lung (3.2-fold), and heart (1.8-fold, rightmost column, supplemental Table 1 ).
DISCUSSION
To our knowledge, this article reports the first-in-human use of 11 C-PBR28, a potential cellular marker of inflammation. On the basis of human biodistribution data, 11 C-PBR28 caused only modest radiation exposure, with an effective dose of 6.6 mSv/MBq.
Effect of Receptor Availability
We examined the effect of receptor availability in both monkeys using preblockade and in humans via a single unusual subject. The blockade or absence of these receptor reservoirs had similar effects in both species-that is, decreased radiation to organs with high densities of PBRs and increased radiation to organs associated with metabolism and excretion. For example, radiation dose decreased 60%-70% to lung and 70%-90% to spleen (supplemental Table 1 ), and both of these organs have high densities of PBRs. In the absence of receptor binding, the plasma concentration of the radioligand increases and more radiopharmaceutical is exposed to organs of elimination. Thus, radiation burden to liver was increased 70%-90% in human and monkey, respectively (supplemental Table 1 ). Receptor blockade also increased urinary elimination of radioactivity, with radiation to urinary bladder increased 70% in monkey and 20% in human. In summary, both monkey and human showed expected effects of receptor availability. The radioligand's distribution, which by definition is the temporary sequestration of a drug, was decreased to organs with high receptor densities, and its elimination was increased via metabolism and excretion.
Monkey as Model for Human
Is the monkey an adequate model for human dosimetry? Our biodistribution studies in baseline monkeys (i.e., without receptor blockade) overestimated the effective dose in humans by 60% (supplemental Table 1 , far right column). Although a sizeable overestimation, the resulting effective dose (10.3 mSv/MBq) was still within the overall dose range of 12 representative 11 C-labeled radioligands for brain imaging (supplemental Table 2 ). The higher effective dose to monkeys compared with humans was caused primarily by greater exposure to brain (4-fold), lung (3.2-fold), and heart wall (1.8-fold) (supplemental Table 1 , far right column). These organs all have high PBR densities (15) (16) (17) (18) . In summary, the 60% overestimation of human effective dose was likely caused by the higher PBR binding potential in monkey brain, lung, and heart wall.
Comparison with Other Radioligands
Calculated as the effective dose from human biodistribution studies, the radiation exposure from 11 C-PBR28 (6.6 mSv/MBq) was similar to that of 11 other radioligands used in brain imaging (supplemental Table 2 ). Of the 12 ligands listed, 11 are tightly distributed, with a range of 4.3 to 7.0 mSv/MBq. 11 C-WAY100635, a radioligand for serotonin 5-HT 1A receptors, is a marked outlier, with an effective dose of 14.1 mSv/MBq (supplemental Table 2 ). The high effective dose of 11 C-WAY 100635 was caused by the rapid and substantial urinary excretion of radioactivity. About 80% of injected activity accumulated in the bladder within 1 h and caused unusually high doses to this organ and kidneys. In fact, the rapidity of the urinary excretion of 11 C-WAY 100635 may provide a practical upper limit on radiation exposures for 11 C agents excreted via this route. In the absence of a single predominant mode of elimination (e.g., urinary excretion for 11 C-WAY 100635), 11 C-labeled radioligands are likely to have an effective dose of about 6-7 mSv/MBq.
CONCLUSION
The novel radioligand 11 C-PBR28 caused relatively modest radiation burdens, similar to several other 11 C-radioligands used for brain imaging. For unknown reasons, one healthy subject had negligible uptake in organs with high PBR densities. The uptake in this unusual human subject was similar to that in a monkey with preblockade of receptors using high doses of nonradioactive PK 11195. Blockade or absence of receptors was associated with decreased radiation burden to organs with high PBR densities and enhanced uptake in excretory and metabolic pathways. Residence times in baseline conditions were averaged over 3 studies using 2 monkeys. One preblocked study was performed by injecting 10.7 mg/kg of nonradioactive PK 11195 three minutes before the radioligand.
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